Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stevia leaf extract has potential as anticancer treatment, researchers find

2.

Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.

3.

Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness

4.

Review looks at potential treatment targets in the tumor microenvironment.

5.

EVP Beats Cisplatin for Resectable MIBC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot